References
Pfeffer MA, Burdmann EA, Chen C-Y, Cooper ME, de Zeeuw D, Eckardt K-U, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361:2019–32.
Singh AK, Szczech L, Tang KL, Barnhart HX, Sapp S, Wolfson M, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085–98.
Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071–84.
Szczech A, Barnhart HX, Inrig JK, Reddan DN, Sapp S, Califf RM, et al. Secondary analysis of the CHOIR trial epoetin-alfa dose and achieved hemoglobin outcomes. Kidney Int. 2008;74:791–8.
KDOQI Clinical Practice Guidelines and Clinical Practice Recommendation for Anemia in Chronic Kidney Disease. Am J Kidney Dis. 2007;50:471–530.
Conflict of interest statement
There is no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Kuriyama, S. The target hemoglobin in non-dialysis CKD: still a matter for debate?. Clin Exp Nephrol 14, 298–299 (2010). https://doi.org/10.1007/s10157-010-0280-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10157-010-0280-5